|
| Wednesday, August 2, 2023 |
|
|
Sewio Reports Record-Breaking Fiscal Year |
| Sewio, a UWB-based real-time location system (RTLS) vendor, announces an exceptional 71% annual billing growth for FY 2022, showcasing its accelerated adoption and recognition as first-time-right technology for Industrial RTLS. more info >> |
|
| Tuesday, August 1, 2023 |
|
|
Opgal, a World Leader in Optical Gas Imaging Solutions for the Oil and Gas Industry, Adds In-Camera Quantification Feature to Its Optical Gas Imaging Camera |
| Opgal, a world leader in Optical Gas Imaging solutions for the oil and gas industry, adds In-Camera quantification feature to its EyeCGas 2.0 Optical Gas Imaging Camera. more info >> |
|
|
Innovative Real Estate Development featuring Surfing Opens in Brazil |
| JHSF, owners of the luxury brand Fasano(TM), brought the same classic elegance to a pool party like no other at the Grand Opening of Boa Vista Village in Brazil. more info >> |
|
|
Vasileios Mingos Joins Health-ISAC as European Operations Director |
| Health Information Sharing and Analysis Center (Health-ISAC) has announced Vasileios Mingos has joined the organization and will serve as European Operations Director. Mingos will oversee all Health-ISAC European Operations, the European Regional Threat Operations Center, and represent Health-ISAC throughout Europe. more info >> |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
| Friday, July 28, 2023 |
|
|
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients |
| Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. more info >> |
|
| Thursday, July 27, 2023 |
|
|
瑞科爾系統宣布提名Sanjay Sarma教授和Tim Davenport擔任新董事會成員 |
| 瑞科爾系統公司（NASDAQ：REKR）是一家值得信賴的全球權威機構，利用最先進的人工智能和機器學習技術開發和提供道路智能化解決方案。今天，公司宣布將在即將舉行的股東年度大會上提名兩位新董事。新加入董事會的成員分別是Sanjay Sarma教授和Tim Davenport先生。 more info >> |
|
|
瑞科尔系统宣布提名Sanjay Sarma教授和Tim Davenport担任新董事会成员 |
| 瑞科尔系统公司（NASDAQ：REKR）是一家值得信赖的全球权威机构，利用最先进的人工智能和机器学习技术开发和提供道路智能化解决方案。今天，公司宣布将在即将举行的股东年度大会上提名两位新董事。新加入董事会的成员分别是Sanjay Sarma教授和Tim Davenport先生。 more info >> |
|
|
Digital Business Card Company Mobilo Secures $4.1M in Seed Funding |
| Networking just got an upgrade. Mobilo, the maker of the first smart business card for teams and digital business card scene, has raised $4.1 million in seed funding. Thanks to Deepwork Capital, TMT Investments, and some forward-thinking Dutch angel investors, the company is primed to make artificial intelligence (AI) the new best friend of your networking events and meetings, turning casual encounters into lead-generation opportunities. more info >> |
|
|
Rekor Systems Announces Nomination of Professor Sanjay Sarma and Tim Davenport As New Board Directors |
| Rekor Systems, Inc. (NASDAQ:REKR) ("Rekor" or the "Company"), a trusted global authority in developing and delivering roadway intelligence using state-of-the-art AI and machine learning today announced that it will nominate two new directors for election at the Company's upcoming annual meeting of shareholders. more info >> |
|
|
|
|
